TCP-25 gel is well-tolerated by individuals with recessive dystrophic epidermolysis bullosa (RDEB) and may effectively accelerate wound healing, according to a Phase 1 trial. The Phase 1 trial (NCT05378997) compared TCP-25 administered in conjunction with standard care to standard care alone over…
A new mesh-free dressing developed using lipidocolloid technology (TLC) promotes the healing of various types of skin wounds, including those associated with fragile skin caused by epidermolysis bullosa (EB). That’s according to data from the HEAL clinical trial (NCT03640871), which evaluated the new dressing in 78…
Doubling the standard dose of the gene therapy Vyjuvek (beremagene geperpavec) successfully healed widespread wounds in a woman with recessive dystrophic epidermolysis bullosa (RDEB) without causing side effects, a new case report shows. While the topical gel is already approved in the U.S. to treat the disease, the…
Becoming educated and informed about epidermolysis bullosa is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your EB journey.
There is no cure for EB yet, but there are treatments that can help manage the disease. Learn more about the approved and experimental therapies here.
Get regular updates to your inbox.
